DGAP-News: Sangui BioTech International Inc.: Start of Granulox-Sales in Greece scheduled for October 31, 2013
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Alliance
Sangui BioTech International Inc.: Start of Granulox-Sales in Greece
scheduled for October 31, 2013
10.09.2013 / 16:30
---------------------------------------------------------------------
Sangui BioTech: Start of Granulox-Sales in Greece scheduled for October 31,
2013
Witten, Germany, September 10, 2013 - Ramma Dental SA, Athens, has assumed
responsibility for distributing the wound therapeutic Granulox in Greece
with immediate effect. A contract to this effect was signed between Ramma
Dental and SastoMed GmbH, which holds the global distribution rights as
licensee. Actual sales are scheduled to begin on the occasion of the Greek
Wound Management Congress on October 31, 2013.
Established in 1992 by CEO Ioannis Katsiropoulos, Ramma Dental initially
specialized in import and distribution of medical products in the fields of
surgery and in particular dental surgery ('ramma' being the Greek word for
suture). Since then the scope of its product portfolio has expanded
considerably. Ramma Dental serves as distribution partner for global
medical groups such as Johnson&Johnson or Integra Life Sciences. Since
2005 Ramma Dental has also been selling wound care products on behalf of
3M.
'In our country, the demand for special products for chronic wounds has
increased noticeably', emphasizes Ioannis Katsiropoulos. 'Granulox as an
innovative and effective wound therapeutic is an important complement of
our respective product portfolio. Not only is it unmatched in
effectiveness. This effectiveness also helps to reduce treatment costs. We
are convinced that it will be highly appreciated by patients suffering from
chronic wounds as well as by healthcare professionals.'
Michael Sander, SastoMed Managing Director, underlines: 'Ramma Dental is a
well established, yet fast growing distributor. Thanks to its extended
customer base ranging from wholesalers to hospitals and to the individual
patient our new partner will tap promising sales potential in the Greek
market with its almost 11 million inhabitants. We are looking forward to
cooperating for the benefit of the patients and of both our enterprises.'
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
End of financial news
---------------------------------------------------------------------
10.09.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
229819 10.09.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Intelimax Launches New Daily Fantasy Sports Platform on DraftTeam.com
Datum: 10.09.2013 - 16:30 Uhr
Sprache: Deutsch
News-ID 295201
Anzahl Zeichen: 3779
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 254 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc.: Start of Granulox-Sales in Greece scheduled for October 31, 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
